Clinical evaluation of pazufloxacin mesilate for severe refractory infections.
|
Accession number;00A0829649
|
| Title;Clinical evaluation of pazufloxacin mesilate for severe refractory infections. |
| Author;
SHIMADA KAORU
(Tokyo Senbai Hosp.)
NAKAI YUUSHI
(Sendai Kosei Hosp.)
NIIZUMA KAZUNAO
(Fukushima Prefect. Aizu Hosp.)
INAMATSU TAKASHI
(Tokyo Metrop, Geriatr. Hosp.)
KOYAMA MASARU
(Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc. Tokyo Kyosai Hosp.)
MATSUOKA YASUO
(Kawasaki Munic. Kawasaki Hosp.)
ODAGIRI SHIGEKI
(Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center)
KARINO TAKAYUKI
(Kawasaki Med. Sch., Kawasaki Hosp.)
SAKAMOTO TASUKU
(Hansuikai Ainokinenbyoin)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.8;PAGE.673-683(2000)
|
| Figure&Table&Reference;FIG.1, TBL.9, REF.8 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The clinical efficacy, safety and usefulness of pazufloxacin (PZFX) mesilate, a new quinolone for injection, were evaluated in a clinical study of patients with sepsis, infectious endocarditis and empyema resulting in severe refractory infections. PZFX mesilate was administered by intravenous drip infusion at a dose of 500 mg two or three times a day. A total of 9 cases were enrolled in this study, and the clinical efficacy of PZFX mesilate was evaluated in 7 cases. Eight cases were evaluated for side effects, laboratory findings and overall safety, and 7 cases were evaluated for utility. The clinical efficacy rate was 2/2 for sepsis and 3/5 for empyema. The efficacy rate in patients who had responded poorly to other antibiotic treatments was 2/2. The causative organisms were detected in 2 patients with sepsis. One case was caused by a monomicrobial infection of Escherichia coli, while the second case was caused by a polymicrobial infection of E. coli and Enterococcus faecalis. The monomicrobial infection was eradicated by the PZFX treatment, but the outcome of the polymicrobial infection is unknown because bacteriological tests were not performed after the administration of PZFX. The elimination rate of the causative organisms was thus 1/1. The causative organisms were detected in 1 patient with empyema, who had a monomicrobial infection of Streptococcus intermedius. The infection persisted despite treatment, so the elimination rate of the causative organisms was 0/1. Delirium was observed as a side effect in 1 case, and the incidence of all side effects was 1/8. Abnormal laboratory findings were observed in 2 cases, and the incidence of abnormal laboratory findings was 2/8. Eosinophilia was observed in one case, while the second case had an elevated Al-P level. The overall safety of the treatment was evaluated to be 5/8. The utility of PZFX treatment was evaluated to be 1/2 for sepsis and 3/5 for empyema.... (author abst.) |
|
|
|
Related Articles;
|
|
